Trial reportBMC anesthesiology2025
Effect of remimazolam on inflammatory reaction after ureteroscopic lithotripsy: a randomised controlled trial.
Trial report in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundUreteral stone lithotripsy may cause a strong inflammatory response and may be associated with patient outcomes. In clinical practice, remimazolam has been widely used for induction and maintenance of general anesthesia. The purpose of this study is to investigate the effect of remimazolam on the postoperative inflammatory response in patients undergoing ureteral lithotripsy.
methodThe trial was registered at the China Clinical Trial Registration Center (ChiCTR2300070006) on March 31, 2023. The study included 80 patients who underwent lithotripsy for ureteral stones, and they were divided into two groups. Patients in the remimazolam group (n = 40) or propofol group (n = 40) received sufentanil and cisatracurium in combination for induction and maintenance of anesthesia. The levels of interleukin-6 (IL-6), Tumor necrosis factor (TNF)-α, C-reactive protein (CRP) and procalcitonin (PCT) were measured before and 24 h after operation. The recovery time, recovery quality score and postoperative complications were recorded.
resultCompared with the propofol group, the changes of IL-6, TNF-α and CRP in the remimazolam group were significantly decreased before and after operation (p < 0.05), but the changes of PCT before and after operation were not significantly different (P > 0.05). The time of extubation was shorter in the remimazolam group than that in the propofol group (p < 0.05), but the scores of MOAA/s and Rass in the remimazolam group were lower than that in the propofol group within 20 min after operation (p < 0.05), there was no significant difference in the incidence of complications between the two groups.
conclusionRemimazolam is effective in reducing the 24-hour inflammatory response after ureteral stone lithotripsy and is safe and effective for use in this procedure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.